Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;107(11):2725-2731.
doi: 10.3324/haematol.2022.280917.

Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis

Sandrine Lemoine  1 , Clelia Mornet  2 , Isabelle Quintin-Roue  3 , Marie-Christine Rousselet  4 , Laurane Cottin  1 , Aurélie Georgeais  5 , Ludovic Dubouis  6 , Françoise Boyer  7 , Corentin Orvain  8 , Clara Caillon  9 , Maxime Renard  10 , Valoris Le Brun  11 , Lenaig Le Clech  12 , Jean-Christophe Ianotto  13 , Emmanuelle Génin  14 , Barbara Burroni  15 , Valérie Ugo  1 , Damien Luque Paz  1 , Eric Lippert  16
Affiliations

Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis

Sandrine Lemoine et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagnoses modified, mutations detected by next-generation sequencing in the triple-negative cohort, and incidence of thrombotic events in untreated and treated patients in the triple-negative groups compared to JAK2- and CALR-mutated controls. (A). Initial and modified diagnoses after bone marrow review and next-generation sequencing (NGS) analysis. Top. Repartition of diagnoses according to successive classifications: (left) at initial diagnosis (before bone marrow biopsy review by GEBOM and NGS); (middle) after bone marrow biopsy review; (right) after targeted NGS. Bottom. Sankey diagram showing the proportion of patients whose diagnosis was modified by bone marrow biopsy review and/or NGS analysis. (B). Molecular landscape of the whole cohort. (Left) number of mutations per gene classified per category (pathogenic, likely pathogenic, germline and of uncertain significance); (left) repartition of genes mutated according to diagnosis before targeted NGS analysis (MPN, no-MPN, uncertain diagnosis); (right) repartition of mutated genes according to diagnosis after targeted NGS analysis (MPN, no-MPN, constitutional thrombocytopenia). (C). Thrombosis-free survival in untreated and treated patients with triple-negative thrombocytosis compared to JAK2- and CALR-mutated controls. Survival curves are represented by Kaplan-Meier plots with log-rank associated tests and Cox models for multivariate analysis. Statistics were performed with R software (v4.0.3, Vienna, Austria). MPN: myeloproliferative neoplasm (i.e., essential thrombocythemia); no-MPN : histology/NGS not in favor of myeloproliferative neoplasm; VUS: variant of unknown significance.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R, et al. . The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. - PubMed
    1. Grinfeld J, Nangalia J, Baxter EJ, et al. . Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416-1430. - PMC - PubMed
    1. Angona A, Fernández-Rodríguez C, Alvarez-Larrán A, et al. . Molecular characterisation of triple negative essential thrombocythaemia patients by platelets analysis and targeted sequencing. Blood Cancer J. 2016;6(8):e463. - PMC - PubMed
    1. Michail O, McCallion P, McGimpsey J, et al. . Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort. J Clin Pathol. 2021;74(12):808-811. - PubMed
    1. Acha P, Xandri M, Fuster-Tormo F, et al. . Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. Am J Hematol. 2019;94(10):E264-E267. - PubMed